<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002543</url>
  </required_header>
  <id_info>
    <org_study_id>MCW-ARRC-22393</org_study_id>
    <secondary_id>CDR0000063244</secondary_id>
    <secondary_id>CHW-93/59</secondary_id>
    <secondary_id>NCI-T93-0097D</secondary_id>
    <nct_id>NCT00002543</nct_id>
  </id_info>
  <brief_title>Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors</brief_title>
  <official_title>GALLIUM NITRATE FOR THE TREATMENT OF MALIGNANT TUMORS, A PHASE I STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: : Phase I trial to study the effectiveness of gallium nitrate in young patients who&#xD;
      have malignant brain tumors, neuroblastoma, rhabdomyosarcoma, non-Hodgkin's lymphoma, or&#xD;
      refractory solid tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the safety and side effects of gallium nitrate (GAN) when used as an&#xD;
      anticancer agent in pediatric patients with refractory solid tumors, including malignant&#xD;
      brain tumors, neuroblastoma, rhabdomyosarcoma, and non-Hodgkin's lymphoma. II. Evaluate these&#xD;
      side effects in these patients.&#xD;
&#xD;
      OUTLINE: Single-Agent Chemotherapy. Gallium Nitrate, GAN, NSC-15200.&#xD;
&#xD;
      PROJECTED ACCRUAL: At least 3 patients will be accrued at each dose studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1995</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Lymphoma</condition>
  <condition>Neuroblastoma</condition>
  <condition>Sarcoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gallium nitrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Biopsy-proven rhabdomyosarcoma, non-Hodgkin's lymphoma, or other&#xD;
        solid tumor refractory to conventional therapy or for which no effective curative therapy&#xD;
        is known Re-biopsy required if disease recurs more than 2 years after initial diagnosis&#xD;
        recommended if radiographic abnormalities suggest tumor recurrence within 5 months of&#xD;
        completing radiotherapy or chemotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 21 and under at diagnosis Performance status: Karnofsky&#xD;
        50%-100% Life expectancy: More than 4 weeks Hematopoietic: (unless extensive bone marrow&#xD;
        involvement) ANC greater than 750 Platelets greater than 75,000 Hepatic: Not specified&#xD;
        Renal: Creatinine normal for age OR Glomerular filtration rate at least 50 mL/min per 1.73&#xD;
        square meters Other: Adequate nutritional status No serious uncontrolled infection No&#xD;
        pregnant or nursing women&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: At least 2 weeks since other anticancer therapy and recovered&#xD;
        Prior radiotherapy or surgery for symptomatic lesions allowed provided site of evaluable&#xD;
        disease remains untreated Prior bone marrow or stem cell transplantation allowed No&#xD;
        concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry T. Whelan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marlene &amp; Stewart Greenebaum Cancer Center, University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Floating Hospital Infants and Children</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>October 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2004</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallium nitrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

